Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled Phase 2 study of ivermectin HUVE-19 in symptomatic COVID-19
2020-002091-12Phase 2Completed
- Sponsor
- Huvepharma
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin HUVE-19 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Virological clearance at Day 7. Started May 2020; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002091-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002091-12.